메뉴 건너뛰기




Volumn 18, Issue 11, 2014, Pages 1339-1354

Placental growth factor in cancer

Author keywords

Angiogenesis; Cancer; Inflammation; Macrophage polarization; Metastasis; Placental growth factor; Targeted therapy

Indexed keywords

PLACENTAL GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PLACENTA PROTEIN;

EID: 84911483877     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.948420     Document Type: Review
Times cited : (62)

References (142)
  • 1
    • 0026052391 scopus 로고
    • Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor
    • Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267-71
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 9267-9271
    • Maglione, D.1    Guerriero, V.2    Viglietto, G.3
  • 2
    • 84856874924 scopus 로고    scopus 로고
    • The discovery of placenta growth factor and its biological activity
    • De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44:1-9
    • (2012) Exp Mol Med , vol.44 , pp. 1-9
    • De Falco, S.1
  • 3
    • 0029678008 scopus 로고    scopus 로고
    • The placenta growth factor gene of the mouse
    • DiPalma T, Tucci M, Russo G, et al. The placenta growth factor gene of the mouse. Mamm Genome 1996;7:6-12
    • (1996) Mamm Genome , vol.7 , pp. 6-12
    • DiPalma, T.1    Tucci, M.2    Russo, G.3
  • 4
    • 0027421333 scopus 로고
    • Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    • Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-9
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 10705-10709
    • Kendall, R.L.1    Thomas, K.A.2
  • 5
    • 0032575576 scopus 로고    scopus 로고
    • Neuropilin-1 is a placenta growth factor-2 receptor
    • Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8
    • (1998) J Biol Chem , vol.273 , pp. 22272-22278
    • Migdal, M.1    Huppertz, B.2    Tessler, S.3
  • 6
    • 0032890336 scopus 로고    scopus 로고
    • Structure, expression and receptor-binding properties of placenta growth factor (PlGF)
    • Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40
    • (1999) Curr Top Microbiol Immunol , vol.237 , pp. 31-40
    • Persico, M.G.1    Vincenti, V.2    DiPalma, T.3
  • 7
    • 84880079373 scopus 로고    scopus 로고
    • Proteolytic processing regulates placental growth factor activities
    • Hoffmann DC, Willenborg S, Koch M, et al. Proteolytic processing regulates placental growth factor activities. J Biol Chem 2013;288:17976-89
    • (2013) J Biol Chem , vol.288 , pp. 17976-17989
    • Hoffmann, D.C.1    Willenborg, S.2    Koch, M.3
  • 8
    • 84894256030 scopus 로고    scopus 로고
    • Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing
    • Martino MM, Briquez PS, Guc E, et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 2014;343:885-8
    • (2014) Science , vol.343 , pp. 885-888
    • Martino, M.M.1    Briquez, P.S.2    Guc, E.3
  • 9
    • 19244379078 scopus 로고    scopus 로고
    • Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
    • Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83
    • (2001) Nat Med , vol.7 , pp. 575-583
    • Carmeliet, P.1    Moons, L.2    Luttun, A.3
  • 10
    • 84899136534 scopus 로고    scopus 로고
    • Epigenetic control of hypoxia inducible factor-1alpha-dependent expression of placental growth factor in hypoxic conditions
    • Tudisco L, Della Ragione F, Tarallo V, et al. Epigenetic control of hypoxia inducible factor-1alpha-dependent expression of placental growth factor in hypoxic conditions. Epigenetics 2014;9:600-10
    • (2014) Epigenetics , vol.9 , pp. 600-610
    • Tudisco, L.1    Della Ragione, F.2    Tarallo, V.3
  • 11
    • 56749174211 scopus 로고    scopus 로고
    • FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy?
    • Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56
    • (2008) Nat Rev Cancer , vol.8 , pp. 942-956
    • Fischer, C.1    Mazzone, M.2    Jonckx, B.3
  • 12
    • 84874760414 scopus 로고    scopus 로고
    • Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma
    • Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013;152:1065-76
    • (2013) Cell , vol.152 , pp. 1065-76
    • Snuderl, M.1    Batista, A.2    Kirkpatrick, N.D.3
  • 13
    • 84872197632 scopus 로고    scopus 로고
    • Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs
    • Hedlund EM, Yang X, Zhang Y, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 2013;110:654-9
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 654-659
    • Hedlund, E.M.1    Yang, X.2    Zhang, Y.3
  • 14
  • 15
    • 84879288021 scopus 로고    scopus 로고
    • PlGF: A multitasking cytokine with disease-restricted activity
    • Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012;2:doi: 10.1101/cshperspect.a011056
    • (2012) Cold Spring Harb Perspect Med , vol.2
    • Dewerchin, M.1    Carmeliet, P.2
  • 16
    • 84863124190 scopus 로고    scopus 로고
    • Role of placenta growth factor in cancer and inflammation
    • Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med 2012;44:10-19
    • (2012) Exp Mol Med , vol.44 , pp. 10-19
    • Kim, K.J.1    Cho, C.S.2    Kim, W.U.3
  • 17
    • 84894632560 scopus 로고    scopus 로고
    • Antiangiogenesis therapy: An update after the first decade
    • De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med 2014;29:1-11
    • (2014) Korean J Intern Med , vol.29 , pp. 1-11
    • De Falco, S.1
  • 18
    • 0028134936 scopus 로고
    • Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
    • Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54
    • (1994) J Biol Chem , vol.269 , pp. 25646-25654
    • Park, J.E.1    Chen, H.H.2    Winer, J.3
  • 19
    • 0141721621 scopus 로고    scopus 로고
    • Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders
    • Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1:1356-70
    • (2003) J Thromb Haemost , vol.1 , pp. 1356-1370
    • Autiero, M.1    Luttun, A.2    Tjwa, M.3
  • 20
    • 84880863720 scopus 로고    scopus 로고
    • The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands
    • Anisimov A, Leppanen VM, Tvorogov D, et al. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal 2013;6:ra52
    • (2013) Sci Signal , vol.6 , pp. ra52
    • Anisimov, A.1    Leppanen, V.M.2    Tvorogov, D.3
  • 21
    • 0029849637 scopus 로고    scopus 로고
    • In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor
    • Cao Y, Linden P, Shima D, et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996;98:2507-11
    • (1996) J Clin Invest , vol.98 , pp. 2507-2511
    • Cao, Y.1    Linden, P.2    Shima, D.3
  • 22
    • 0028956308 scopus 로고
    • Purification and characterization of a naturally occurring vascular endothelial growth factor.Placenta growth factor heterodimer
    • DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem 1995;270:7717-23
    • (1995) J Biol Chem , vol.270 , pp. 7717-7723
    • DiSalvo, J.1    Bayne, M.L.2    Conn, G.3
  • 23
    • 79952277312 scopus 로고    scopus 로고
    • Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model
    • Brave SR, Eberlein C, Shibuya M, et al. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010;13:337-47
    • (2010) Angiogenesis , vol.13 , pp. 337-347
    • Brave, S.R.1    Eberlein, C.2    Shibuya, M.3
  • 24
    • 77950202451 scopus 로고    scopus 로고
    • A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization
    • Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70:1804-13
    • (2010) Cancer Res , vol.70 , pp. 1804-1813
    • Tarallo, V.1    Vesci, L.2    Capasso, O.3
  • 25
    • 84864829438 scopus 로고    scopus 로고
    • A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism
    • Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res 2011;1:265-74
    • (2011) Am J Cancer Res , vol.1 , pp. 265-274
    • Tarallo, V.1    Tudisco, L.2    De Falco, S.3
  • 26
    • 84864856289 scopus 로고    scopus 로고
    • The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis
    • Cudmore MJ, Hewett PW, Ahmad S, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun 2012;3:972
    • (2012) Nat Commun , vol.3 , pp. 972
    • Cudmore, M.J.1    Hewett, P.W.2    Ahmad, S.3
  • 27
    • 29244460998 scopus 로고    scopus 로고
    • Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A
    • Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005;16:1422-8
    • (2005) Hum Gene Ther , vol.16 , pp. 1422-1428
    • Roy, H.1    Bhardwaj, S.2    Babu, M.3
  • 28
    • 33746602209 scopus 로고    scopus 로고
    • Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor
    • Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 2006;169:643-54
    • (2006) Am J Pathol , vol.169 , pp. 643-654
    • Marcellini, M.1    De Luca, N.2    Riccioni, T.3
  • 29
    • 0037703184 scopus 로고    scopus 로고
    • Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
    • Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43
    • (2003) Nat Med , vol.9 , pp. 936-943
    • Autiero, M.1    Waltenberger, J.2    Communi, D.3
  • 30
    • 77950865464 scopus 로고    scopus 로고
    • Vascular endothelial growth factor B controls endothelial fatty acid uptake
    • Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-21
    • (2010) Nature , vol.464 , pp. 917-921
    • Hagberg, C.E.1    Falkevall, A.2    Wang, X.3
  • 31
    • 17044441694 scopus 로고    scopus 로고
    • Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers
    • Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002;1:99-108
    • (2002) Cancer Cell , vol.1 , pp. 99-108
    • Eriksson, A.1    Cao, R.2    Pawliuk, R.3
  • 32
    • 33646227427 scopus 로고    scopus 로고
    • Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models
    • Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006;66:3971-7
    • (2006) Cancer Res , vol.66 , pp. 3971-3977
    • Xu, L.1    Cochran, D.M.2    Tong, R.T.3
  • 33
    • 36349030423 scopus 로고    scopus 로고
    • Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis
    • Schomber T, Kopfstein L, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 2007;67:10840-8
    • (2007) Cancer Res , vol.67 , pp. 10840-10848
    • Schomber, T.1    Kopfstein, L.2    Djonov, V.3
  • 34
    • 67650380136 scopus 로고    scopus 로고
    • Biomarkers of response and resistance to antiangiogenic therapy
    • Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 327-338
    • Jain, R.K.1    Duda, D.G.2    Willett, C.G.3
  • 35
    • 79952271819 scopus 로고    scopus 로고
    • Placental growth factor upregulation is a host response to antiangiogenic therapy
    • Bagley RG, Ren Y, Weber W, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res 2011;17:976-88
    • (2011) Clin Cancer Res , vol.17 , pp. 976-988
    • Bagley, R.G.1    Ren, Y.2    Weber, W.3
  • 36
    • 72249119811 scopus 로고    scopus 로고
    • VEGF-A: A critical regulator of blood vessel growth
    • Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158-63
    • (2009) Eur Cytokine Netw , vol.20 , pp. 158-163
    • Ferrara, N.1
  • 37
    • 79956328903 scopus 로고    scopus 로고
    • Molecular mechanisms and clinical applications of angiogenesis
    • Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307
    • (2011) Nature , vol.473 , pp. 298-307
    • Carmeliet, P.1    Jain, R.K.2
  • 38
    • 84882805811 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth
    • Yang X, Zhang Y, Yang Y, et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA 2013;110:13932-7
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 13932-13937
    • Yang, X.1    Zhang, Y.2    Yang, Y.3
  • 39
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
    • (2011) Cell , vol.144 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 40
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 41
    • 77950948813 scopus 로고    scopus 로고
    • Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
    • Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13:16-28
    • (2010) Drug Resist Updat , vol.13 , pp. 16-28
    • Abdollahi, A.1    Folkman, J.2
  • 42
    • 66649112192 scopus 로고    scopus 로고
    • "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF
    • Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53
    • (2009) Clin Cancer Res , vol.15 , pp. 3648-3653
    • Loges, S.1    Schmidt, T.2    Carmeliet, P.3
  • 43
    • 35548982639 scopus 로고    scopus 로고
    • Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels
    • Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75
    • (2007) Cell , vol.131 , pp. 463-475
    • Fischer, C.1    Jonckx, B.2    Mazzone, M.3
  • 44
    • 77950960449 scopus 로고    scopus 로고
    • Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
    • Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141:178-90
    • (2010) Cell , vol.141 , pp. 178-190
    • Van De Veire, S.1    Stalmans, I.2    Heindryckx, F.3
  • 45
    • 78651461701 scopus 로고    scopus 로고
    • HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF
    • Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44
    • (2011) Cancer Cell , vol.19 , pp. 31-44
    • Rolny, C.1    Mazzone, M.2    Tugues, S.3
  • 46
    • 77950953984 scopus 로고    scopus 로고
    • PlGF blockade does not inhibit angiogenesis during primary tumor growth
    • Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77
    • (2010) Cell , vol.141 , pp. 166-177
    • Bais, C.1    Wu, X.2    Yao, J.3
  • 47
    • 79960984152 scopus 로고    scopus 로고
    • Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
    • Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 2011;108:11590-5
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 11590-11595
    • Yao, J.1    Wu, X.2    Zhuang, G.3
  • 48
    • 0036344495 scopus 로고    scopus 로고
    • Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    • Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40
    • (2002) Nat Med , vol.8 , pp. 831-840
    • Luttun, A.1    Tjwa, M.2    Moons, L.3
  • 49
    • 84879103653 scopus 로고    scopus 로고
    • Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway
    • Wei SC, Tsao PN, Weng MT, et al. Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci 2013;20:39
    • (2013) J Biomed Sci , vol.20 , pp. 39
    • Wei, S.C.1    Tsao, P.N.2    Weng, M.T.3
  • 50
    • 77955744282 scopus 로고    scopus 로고
    • Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation
    • Coenegrachts L, Maes C, Torrekens S, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 2010;70:6537-47
    • (2010) Cancer Res , vol.70 , pp. 6537-6547
    • Coenegrachts, L.1    Maes, C.2    Torrekens, S.3
  • 51
    • 33751267529 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer
    • Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12:6573-84
    • (2006) Clin Cancer Res , vol.12 , pp. 6573-6584
    • Wu, Y.1    Zhong, Z.2    Huber, J.3
  • 52
    • 77954176110 scopus 로고    scopus 로고
    • Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement
    • Taylor AP, Leon E, Goldenberg DM. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer 2010;103:82-9
    • (2010) Br J Cancer , vol.103 , pp. 82-89
    • Taylor, A.P.1    Leon, E.2    Goldenberg, D.M.3
  • 53
    • 84883645896 scopus 로고    scopus 로고
    • Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts
    • Zins K, Thomas A, Lucas T, et al. Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts. Int J Mol Sci 2013;14:17958-71
    • (2013) Int J Mol Sci , vol.14 , pp. 17958-17971
    • Zins, K.1    Thomas, A.2    Lucas, T.3
  • 54
    • 79958732559 scopus 로고    scopus 로고
    • Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1 (+) leukemia
    • Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1 (+) leukemia. Cancer Cell 2011;19:740-53
    • (2011) Cancer Cell , vol.19 , pp. 740-753
    • Schmidt, T.1    Kharabi Masouleh, B.2    Loges, S.3
  • 56
    • 78650841055 scopus 로고    scopus 로고
    • Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-kappaB
    • Levati L, Ruffini F, Muzi A, et al. Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-kappaB. Int J Oncol 2011;38:241-7
    • (2011) Int J Oncol , vol.38 , pp. 241-247
    • Levati, L.1    Ruffini, F.2    Muzi, A.3
  • 57
    • 70350456094 scopus 로고    scopus 로고
    • Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
    • Hedlund EM, Hosaka K, Zhong Z, et al. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci USA 2009;106:17505-10
    • (2009) Proc Natl Acad Sci USA , vol.106 , pp. 17505-17510
    • Hedlund, E.M.1    Hosaka, K.2    Zhong, Z.3
  • 58
    • 66149086950 scopus 로고    scopus 로고
    • Positive and negative modulation of angiogenesis by VEGFR1 ligands
    • Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009;2:re1
    • (2009) Sci Signal , vol.2 , pp. re1
    • Cao, Y.1
  • 59
    • 79953054278 scopus 로고    scopus 로고
    • Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability
    • Cai J, Wu L, Qi X, et al. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One 2011;6:e18076
    • (2011) PLoS One , vol.6 , pp. e18076
    • Cai, J.1    Wu, L.2    Qi, X.3
  • 60
    • 79957894276 scopus 로고    scopus 로고
    • Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
    • Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 417-427
    • Carmeliet, P.1    Jain, R.K.2
  • 61
    • 84872418622 scopus 로고    scopus 로고
    • The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model
    • Heindryckx F, Coulon S, Terrie E, et al. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. J Hepatol 2013;58:319-28
    • (2013) J Hepatol , vol.58 , pp. 319-328
    • Heindryckx, F.1    Coulon, S.2    Terrie, E.3
  • 62
    • 79957904669 scopus 로고    scopus 로고
    • Proangiogenic factor PlGF programs CD11b+ myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors
    • Laurent J, Faes-Van't Hull E, Touvrey C, et al. Proangiogenic factor PlGF programs CD11b+ myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res 2011;71:3781-91
    • (2011) Cancer Res , vol.71 , pp. 3781-3791
    • Laurent, J.1    Faes-Van't Hull, E.2    Touvrey, C.3
  • 63
    • 0037093078 scopus 로고    scopus 로고
    • Placental growth factor is a survival factor for tumor endothelial cells and macrophages
    • Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-52
    • (2002) Cancer Res , vol.62 , pp. 2749-2752
    • Adini, A.1    Kornaga, T.2    Firoozbakht, F.3
  • 64
    • 33845707705 scopus 로고    scopus 로고
    • VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization
    • Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. Faseb J 2006;20:1495-7
    • (2006) Faseb J , vol.20 , pp. 1495-1497
    • Li, B.1    Sharpe, E.E.2    Maupin, A.B.3
  • 65
    • 0037431536 scopus 로고    scopus 로고
    • Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: Potential relationship to post-therapy tumor angiogenesis and recurrence
    • Taylor AP, Rodriguez M, Adams K, et al. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105:158-64
    • (2003) Int J Cancer , vol.105 , pp. 158-164
    • Taylor, A.P.1    Rodriguez, M.2    Adams, K.3
  • 66
    • 77950950894 scopus 로고    scopus 로고
    • Macrophage diversity enhances tumor progression and metastasis
    • Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51
    • (2010) Cell , vol.141 , pp. 39-51
    • Qian, B.Z.1    Pollard, J.W.2
  • 67
    • 84859416688 scopus 로고    scopus 로고
    • Chronic inflammatory states: Their relationship to cancer prognosis and symptoms
    • MacDonald N. Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J R Coll Physicians Edinb 2011;41:246-53
    • (2011) J R Coll Physicians Edinb , vol.41 , pp. 246-253
    • MacDonald, N.1
  • 68
    • 54749092522 scopus 로고    scopus 로고
    • Flt-1 signaling in macrophages promotes glioma growth in vivo
    • Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008;68:7342-51
    • (2008) Cancer Res , vol.68 , pp. 7342-7351
    • Kerber, M.1    Reiss, Y.2    Wickersheim, A.3
  • 69
    • 77951920351 scopus 로고    scopus 로고
    • NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha
    • Ding Y, Huang Y, Song N, et al. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha. J Immunol 2010;184:2593-601
    • (2010) J Immunol , vol.184 , pp. 2593-2601
    • Ding, Y.1    Huang, Y.2    Song, N.3
  • 70
    • 0036733564 scopus 로고    scopus 로고
    • Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis
    • Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56
    • (2002) Am J Pathol , vol.161 , pp. 947-956
    • Schoppmann, S.F.1    Birner, P.2    Stockl, J.3
  • 71
    • 33845767868 scopus 로고    scopus 로고
    • Macrophages regulate the angiogenic switch in a mouse model of breast cancer
    • Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46
    • (2006) Cancer Res , vol.66 , pp. 11238-11246
    • Lin, E.Y.1    Li, J.F.2    Gnatovskiy, L.3
  • 72
    • 24944587964 scopus 로고    scopus 로고
    • Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
    • De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26
    • (2005) Cancer Cell , vol.8 , pp. 211-226
    • De Palma, M.1    Venneri, M.A.2    Galli, R.3
  • 73
    • 31044433663 scopus 로고    scopus 로고
    • Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
    • Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6
    • (2006) Cell , vol.124 , pp. 263-266
    • Condeelis, J.1    Pollard, J.W.2
  • 74
    • 84875492465 scopus 로고    scopus 로고
    • Tumor associated macrophages and neutrophils in tumor progression
    • Galdiero MR, Garlanda C, Jaillon S, et al. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013;228:1404-12
    • (2013) J Cell Physiol , vol.228 , pp. 1404-1412
    • Galdiero, M.R.1    Garlanda, C.2    Jaillon, S.3
  • 75
    • 84892832431 scopus 로고    scopus 로고
    • Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo
    • Jetten N, Verbruggen S, Gijbels MJ, et al. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109-18
    • (2014) Angiogenesis , vol.17 , pp. 109-118
    • Jetten, N.1    Verbruggen, S.2    Gijbels, M.J.3
  • 76
    • 84892497106 scopus 로고    scopus 로고
    • Role of inflammation-associated microenvironment in tumorigenesis and metastasis
    • Gao F, Liang B, Reddy ST, et al. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 2014;14:30-45
    • (2014) Curr Cancer Drug Targets , vol.14 , pp. 30-45
    • Gao, F.1    Liang, B.2    Reddy, S.T.3
  • 77
    • 28644432204 scopus 로고    scopus 로고
    • VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche
    • Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005;438:820-7
    • (2005) Nature , vol.438 , pp. 820-827
    • Kaplan, R.N.1    Riba, R.D.2    Zacharoulis, S.3
  • 79
    • 70349280375 scopus 로고    scopus 로고
    • VEGFR1-activity-independent metastasis formation
    • discussion E5
    • Dawson MR, Duda DG, Fukumura D, et al. VEGFR1-activity-independent metastasis formation. Nature 2009;461:E4; discussion E5
    • (2009) Nature , vol.461 , pp. E4
    • Dawson, M.R.1    Duda, D.G.2    Fukumura, D.3
  • 80
    • 70349464463 scopus 로고    scopus 로고
    • VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation
    • Dawson MR, Duda DG, Chae SS, et al. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One 2009;4:e6525
    • (2009) PLoS One , vol.4 , pp. e6525
    • Dawson, M.R.1    Duda, D.G.2    Chae, S.S.3
  • 81
    • 77955036151 scopus 로고    scopus 로고
    • Premetastatic lung "niche": Is vascular endothelial growth factor receptor 1 activation required?
    • Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res 2010;70:5670-3
    • (2010) Cancer Res , vol.70 , pp. 5670-5673
    • Duda, D.G.1    Jain, R.K.2
  • 82
    • 79955081875 scopus 로고    scopus 로고
    • Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice
    • Van Steenkiste C, Ribera J, Geerts A, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011;53:1629-40
    • (2011) Hepatology , vol.53 , pp. 1629-1640
    • Van Steenkiste, C.1    Ribera, J.2    Geerts, A.3
  • 83
    • 84861147161 scopus 로고    scopus 로고
    • Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma
    • Coulouarn C, Corlu A, Glaise D, et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012;72:2533-42
    • (2012) Cancer Res , vol.72 , pp. 2533-2542
    • Coulouarn, C.1    Corlu, A.2    Glaise, D.3
  • 84
    • 35548934659 scopus 로고    scopus 로고
    • alphaPlGF: A new kid on the antiangiogenesis block
    • Jain RK, Xu L. alphaPlGF: a new kid on the antiangiogenesis block. Cell 2007;131:443-5
    • (2007) Cell , vol.131 , pp. 443-445
    • Jain, R.K.1    Xu, L.2
  • 85
    • 33847407090 scopus 로고    scopus 로고
    • Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts
    • Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007;6:524-31
    • (2007) Mol Cancer Ther , vol.6 , pp. 524-531
    • Taylor, A.P.1    Goldenberg, D.M.2
  • 86
    • 84864883885 scopus 로고    scopus 로고
    • Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model
    • Heindryckx F, Bogaerts E, Coulon SH, et al. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. Eur J Gastroenterol Hepatol 2012;24:1020-32
    • (2012) Eur J Gastroenterol Hepatol , vol.24 , pp. 1020-1032
    • Heindryckx, F.1    Bogaerts, E.2    Coulon, S.H.3
  • 87
    • 84878648598 scopus 로고    scopus 로고
    • Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441
    • Oude Munnink TH, Tamas KR, Lub-de Hooge MN, et al. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441. J Nucl Med 2013;54:929-35
    • (2013) J Nucl Med , vol.54 , pp. 929-935
    • Oude Munnink, T.H.1    Tamas, K.R.2    Lub-de Hooge, M.N.3
  • 88
    • 77951981938 scopus 로고    scopus 로고
    • Ribosome display and selection of human antiplacental growth factor scFv derived from ovarian cancer patients
    • Li F, Su P, Lin C, et al. Ribosome display and selection of human antiplacental growth factor scFv derived from ovarian cancer patients. Protein Pept Lett 2010;17:585-90
    • (2010) Protein Pept Lett , vol.17 , pp. 585-590
    • Li, F.1    Su, P.2    Lin, C.3
  • 89
    • 0030582384 scopus 로고    scopus 로고
    • Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
    • Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8
    • (1996) Biochem Biophys Res Commun , vol.226 , pp. 324-328
    • Kendall, R.L.1    Wang, G.2    Thomas, K.A.3
  • 91
    • 84995743346 scopus 로고    scopus 로고
    • Update on antiangiogenic therapy in colorectal cancer: Aflibercept and regorafenib
    • Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol 2013;4:231-8
    • (2013) J Gastrointest Oncol , vol.4 , pp. 231-238
    • Jitawatanarat, P.1    Wee, W.2
  • 92
    • 84858336778 scopus 로고    scopus 로고
    • A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    • Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2012;125:42-7
    • (2012) Gynecol Oncol , vol.125 , pp. 42-47
    • Colombo, N.1    Mangili, G.2    Mammoliti, S.3
  • 93
    • 84866371169 scopus 로고    scopus 로고
    • A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: A children's oncology group phase I consortium report
    • Glade Bender J, Blaney SM, Borinstein S, et al. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res 2012;18:5081-9
    • (2012) Clin Cancer Res , vol.18 , pp. 5081-5089
    • Glade Bender, J.1    Blaney, S.M.2    Borinstein, S.3
  • 94
    • 84890526897 scopus 로고    scopus 로고
    • Ziv-aflibercept in metastatic colorectal cancer
    • Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics 2014;8:13-25
    • (2014) Biologics , vol.8 , pp. 13-25
    • Patel, A.1    Sun, W.2
  • 95
    • 84908155926 scopus 로고    scopus 로고
    • Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer
    • Epub 2014/04/29
    • Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2014; Epub 2014/04/29
    • (2014) Clin Colorectal Cancer
    • Lee, J.J.1    Chu, E.2
  • 96
    • 80053041612 scopus 로고    scopus 로고
    • Monoclonal antibody TB-403: A first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects
    • Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther 2011;33:1142-9
    • (2011) Clin Ther , vol.33 , pp. 1142-1149
    • Martinsson-Niskanen, T.1    Riisbro, R.2    Larsson, L.3
  • 97
    • 84856829603 scopus 로고    scopus 로고
    • RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo
    • Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC Philadelphia (PA): AACR
    • Rizzo C, Yin Xin X, Packman K, et al. RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC Philadelphia (PA): AACR. Cancer Res 2010;70(8 Suppl):abstract no 1370
    • (2010) Cancer Res , vol.70 , Issue.8
    • Rizzo, C.1    Yin Xin, X.2    Packman, K.3
  • 98
    • 84861307333 scopus 로고    scopus 로고
    • Inhibition of placenta growth factor with TB-403: A novel antiangiogenic cancer therapy
    • Nielsen DL, Sengelov L. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin Biol Ther 2012;12:795-804
    • (2012) Expert Opin Biol Ther , vol.12 , pp. 795-804
    • Nielsen, D.L.1    Sengelov, L.2
  • 99
    • 84856819648 scopus 로고    scopus 로고
    • A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours
    • Lassen U, Nielsen DL, Sorensen M, et al. A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer 2012;106:678-84
    • (2012) Br J Cancer , vol.106 , pp. 678-684
    • Lassen, U.1    Nielsen, D.L.2    Sorensen, M.3
  • 100
    • 84911494164 scopus 로고    scopus 로고
    • Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mAb bevacizumab (BV) in patients with recurrent glioblastoma (GBM)
    • Lassen UN, Chinot OL, McBain C, et al. Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mAb bevacizumab (BV) in patients with recurrent glioblastoma (GBM). J Clin Oncol 2013;31(Suppl):abstract 2092
    • (2013) J Clin Oncol , vol.31
    • Lassen, U.N.1    Chinot, O.L.2    McBain, C.3
  • 101
    • 79955580873 scopus 로고    scopus 로고
    • HCC and angiogenesis: Possible targets and future directions
    • Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301
    • (2011) Nat Rev Clin Oncol , vol.8 , pp. 292-301
    • Zhu, A.X.1    Duda, D.G.2    Sahani, D.V.3
  • 102
    • 0034778395 scopus 로고    scopus 로고
    • Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy
    • Harris AL, Reusch P, Barleon B, et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992-7
    • (2001) Clin Cancer Res , vol.7 , pp. 1992-1997
    • Harris, A.L.1    Reusch, P.2    Barleon, B.3
  • 103
    • 77951729010 scopus 로고    scopus 로고
    • The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma
    • Nagaoka S, Yoshida T, Akiyoshi J, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 2010;23:1647-54
    • (2010) Oncol Rep , vol.23 , pp. 1647-1654
    • Nagaoka, S.1    Yoshida, T.2    Akiyoshi, J.3
  • 104
    • 84872781130 scopus 로고    scopus 로고
    • Increased expression of placental growth factor in high-grade endometrial carcinoma
    • Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep 2013;29:413-18
    • (2013) Oncol Rep , vol.29 , pp. 413-418
    • Coenegrachts, L.1    Schrauwen, S.2    Van Bree, R.3
  • 105
    • 4344620032 scopus 로고    scopus 로고
    • The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer
    • Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004;213:73-82
    • (2004) Cancer Lett , vol.213 , pp. 73-82
    • Chen, C.N.1    Hsieh, F.J.2    Cheng, Y.M.3
  • 106
    • 69549116791 scopus 로고    scopus 로고
    • PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance
    • Escudero-Esparza A, Martin TA, Davies ML, et al. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009;6:239-46
    • (2009) Cancer Genomics Proteomics , vol.6 , pp. 239-246
    • Escudero-Esparza, A.1    Martin, T.A.2    Davies, M.L.3
  • 107
    • 17644379417 scopus 로고    scopus 로고
    • Placenta growth factor expression is correlated with survival of patients with colorectal cancer
    • Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005;54:666-72
    • (2005) Gut , vol.54 , pp. 666-672
    • Wei, S.C.1    Tsao, P.N.2    Yu, S.C.3
  • 108
    • 84865180353 scopus 로고    scopus 로고
    • Is serum placental growth factor a prognostic marker for stage III colorectal cancer patients?
    • Gomceli I, Tez M, Bostanci EB, et al. Is serum placental growth factor a prognostic marker for stage III colorectal cancer patients? Hepatogastroenterology 2012;59:1437-40
    • (2012) Hepatogastroenterology , vol.59 , pp. 1437-1440
    • Gomceli, I.1    Tez, M.2    Bostanci, E.B.3
  • 109
    • 0842343498 scopus 로고    scopus 로고
    • Prognostic significance of plasma placental growth factor levels in renal cell cancer: An association with clinical characteristics and vascular endothelial growth factor levels
    • Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23:4953-8
    • (2003) Anticancer Res , vol.23 , pp. 4953-4958
    • Matsumoto, K.1    Suzuki, K.2    Koike, H.3
  • 110
    • 79959836604 scopus 로고    scopus 로고
    • Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer
    • Rahbari NN, Schmidt T, Falk CS, et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011;11:286
    • (2011) BMC Cancer , vol.11 , pp. 286
    • Rahbari, N.N.1    Schmidt, T.2    Falk, C.S.3
  • 111
    • 78650782829 scopus 로고    scopus 로고
    • Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue
    • Xu HX, Zhu XD, Zhuang PY, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 2011;128:1559-69
    • (2011) Int J Cancer , vol.128 , pp. 1559-1569
    • Xu, H.X.1    Zhu, X.D.2    Zhuang, P.Y.3
  • 112
    • 34047159945 scopus 로고    scopus 로고
    • Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma
    • Ho MC, Chen CN, Lee H, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007;250:237-49
    • (2007) Cancer Lett , vol.250 , pp. 237-249
    • Ho, M.C.1    Chen, C.N.2    Lee, H.3
  • 113
    • 80051549354 scopus 로고    scopus 로고
    • Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases
    • Rahbari NN, Reissfelder C, Muhlbayer M, et al. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 2011;18:2182-91
    • (2011) Ann Surg Oncol , vol.18 , pp. 2182-2191
    • Rahbari, N.N.1    Reissfelder, C.2    Muhlbayer, M.3
  • 114
    • 76649126441 scopus 로고    scopus 로고
    • PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: Prognostic significance
    • Escudero-Esparza A, Martin TA, Douglas-Jones A, et al. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 2010;23:537-44
    • (2010) Oncol Rep , vol.23 , pp. 537-544
    • Escudero-Esparza, A.1    Martin, T.A.2    Douglas-Jones, A.3
  • 115
    • 28244448600 scopus 로고    scopus 로고
    • Placenta growth factor is over-expressed and has prognostic value in human breast cancer
    • Parr C, Watkins G, Boulton M, et al. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005;41:2819-27
    • (2005) Eur J Cancer , vol.41 , pp. 2819-2827
    • Parr, C.1    Watkins, G.2    Boulton, M.3
  • 116
    • 84860330301 scopus 로고    scopus 로고
    • Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer
    • Maae E, Olsen DA, Steffensen KD, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 2012;133:257-65
    • (2012) Breast Cancer Res Treat , vol.133 , pp. 257-265
    • Maae, E.1    Olsen, D.A.2    Steffensen, K.D.3
  • 117
    • 84879416014 scopus 로고    scopus 로고
    • Elevated PLGF contributes to small-cell lung cancer brain metastasis
    • Li B, Wang C, Zhang Y, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 2013;32:2952-62
    • (2013) Oncogene , vol.32 , pp. 2952-2962
    • Li, B.1    Wang, C.2    Zhang, Y.3
  • 118
    • 27644440431 scopus 로고    scopus 로고
    • Expression of Placenta growth factor (PlGF) in nonsmall cell lung cancer (NSCLC) and the clinical and prognostic significance
    • Zhang L, Chen J, Ke Y, et al. Expression of Placenta growth factor (PlGF) in nonsmall cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005;3:68
    • (2005) World J Surg Oncol , vol.3 , pp. 68
    • Zhang, L.1    Chen, J.2    Ke, Y.3
  • 119
    • 78649463119 scopus 로고    scopus 로고
    • Expression of placenta growth factor: An independent factor for prediction of progression and prognosis of oral cancer
    • Cheng SJ, Lee JJ, Kok SH, et al. Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer. Head Neck 2010;32:1363-9
    • (2010) Head Neck , vol.32 , pp. 1363-1369
    • Cheng, S.J.1    Lee, J.J.2    Kok, S.H.3
  • 120
    • 84877621254 scopus 로고    scopus 로고
    • Increased placenta growth factor mRNA level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma
    • Cheng SJ, Cheng SL, Lee JJ, et al. Increased placenta growth factor mRNA level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma. J Formos Med Assoc 2013;112:253-8
    • (2013) J Formos Med Assoc , vol.112 , pp. 253-258
    • Cheng, S.J.1    Cheng, S.L.2    Lee, J.J.3
  • 121
    • 84879469416 scopus 로고    scopus 로고
    • Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients
    • Hilfenhaus G, Gohrig A, Pape UF, et al. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. Endocr Relat Cancer 2013;20:305-19
    • (2013) Endocr Relat Cancer , vol.20 , pp. 305-319
    • Hilfenhaus, G.1    Gohrig, A.2    Pape, U.F.3
  • 122
    • 84872359755 scopus 로고    scopus 로고
    • Exploratory investigation of eight circulating plasma markers in brain tumor patients
    • Ilhan-Mutlu A, Wagner L, Widhalm G, et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev 2013;36:45-55
    • (2013) Neurosurg Rev , vol.36 , pp. 45-55
    • Ilhan-Mutlu, A.1    Wagner, L.2    Widhalm, G.3
  • 123
    • 84862316719 scopus 로고    scopus 로고
    • CD105 and placental growth factor - Potent prognostic factors in childhood acute lymphoblastic leukaemia
    • Sujka-Kordowska P, Malinska A, Ostalska-Nowicka D, et al. CD105 and placental growth factor - potent prognostic factors in childhood acute lymphoblastic leukaemia. Leuk Res 2012;36:846-51
    • (2012) Leuk Res , vol.36 , pp. 846-851
    • Sujka-Kordowska, P.1    Malinska, A.2    Ostalska-Nowicka, D.3
  • 124
    • 80052514816 scopus 로고    scopus 로고
    • Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent mullerian carcinoma
    • Horowitz NS, Penson RT, Duda DG, et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent mullerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig 2011;4:26-33
    • (2011) Clin Ovarian Cancer Other Gynecol Malig , vol.4 , pp. 26-33
    • Horowitz, N.S.1    Penson, R.T.2    Duda, D.G.3
  • 125
    • 30944452436 scopus 로고    scopus 로고
    • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
    • Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9
    • (2005) J Clin Oncol , vol.23 , pp. 8136-8139
    • Willett, C.G.1    Boucher, Y.2    Duda, D.G.3
  • 126
    • 84885458908 scopus 로고    scopus 로고
    • The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer
    • Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 2013;8:e77117
    • (2013) PLoS One , vol.8 , pp. e77117
    • Lieu, C.H.1    Tran, H.2    Jiang, Z.Q.3
  • 127
    • 79954451405 scopus 로고    scopus 로고
    • Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
    • Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9
    • (2011) Br J Cancer , vol.104 , pp. 1262-1269
    • Loupakis, F.1    Cremolini, C.2    Fioravanti, A.3
  • 128
    • 49249087039 scopus 로고    scopus 로고
    • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    • Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8
    • (2008) J Clin Oncol , vol.26 , pp. 3743-3748
    • Rini, B.I.1    Michaelson, M.D.2    Rosenberg, J.E.3
  • 129
    • 84890287907 scopus 로고    scopus 로고
    • A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
    • Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19:6614-23
    • (2013) Clin Cancer Res , vol.19 , pp. 6614-6623
    • Zhu, A.X.1    Finn, R.S.2    Mulcahy, M.3
  • 130
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35
    • (2009) J Clin Oncol , vol.27 , pp. 3027-3035
    • Zhu, A.X.1    Sahani, D.V.2    Duda, D.G.3
  • 131
    • 84875181434 scopus 로고    scopus 로고
    • Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013;19:1557-66
    • (2013) Clin Cancer Res , vol.19 , pp. 1557-1566
    • Zhu, A.X.1    Ancukiewicz, M.2    Supko, J.G.3
  • 132
    • 84865208483 scopus 로고    scopus 로고
    • Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma
    • Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012;17:1063-72
    • (2012) Oncologist , vol.17 , pp. 1063-1072
    • Boige, V.1    Malka, D.2    Bourredjem, A.3
  • 133
    • 84894322176 scopus 로고    scopus 로고
    • Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: Results of a phase I study
    • Hamberg P, Boers-Sonderen MJ, van der Graaf WT, et al. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer 2014;110:888-93
    • (2014) Br J Cancer , vol.110 , pp. 888-893
    • Hamberg, P.1    Boers-Sonderen, M.J.2    Van Der Graaf, W.T.3
  • 134
    • 84895510691 scopus 로고    scopus 로고
    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors
    • Uronis HE, Cushman SM, Bendell JC, et al. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med 2013;2:316-24
    • (2013) Cancer Med , vol.2 , pp. 316-324
    • Uronis, H.E.1    Cushman, S.M.2    Bendell, J.C.3
  • 135
    • 77957366667 scopus 로고    scopus 로고
    • Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer
    • Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27
    • (2010) J Clin Endocrinol Metab , vol.95 , pp. 5018-5027
    • Bass, M.B.1    Sherman, S.I.2    Schlumberger, M.J.3
  • 136
    • 33846149645 scopus 로고    scopus 로고
    • AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
    • Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
    • (2007) Cancer Cell , vol.11 , pp. 83-95
    • Batchelor, T.T.1    Sorensen, A.G.2    Di Tomaso, E.3
  • 137
    • 79960406166 scopus 로고    scopus 로고
    • Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    • de Groot JF, Piao Y, Tran H, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011;17:4872-81
    • (2011) Clin Cancer Res , vol.17 , pp. 4872-4881
    • De Groot, J.F.1    Piao, Y.2    Tran, H.3
  • 138
    • 82555173128 scopus 로고    scopus 로고
    • Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma
    • Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17:7451-61
    • (2011) Clin Cancer Res , vol.17 , pp. 7451-7461
    • Kim, K.B.1    Chesney, J.2    Robinson, D.3
  • 139
    • 0028868639 scopus 로고
    • Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines
    • Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11:1569-79
    • (1995) Oncogene , vol.11 , pp. 1569-1579
    • Viglietto, G.1    Maglione, D.2    Rambaldi, M.3
  • 140
    • 0031458922 scopus 로고    scopus 로고
    • Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors
    • Sowter HM, Corps AN, Evans AL, et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997;77:607-14
    • (1997) Lab Invest , vol.77 , pp. 607-614
    • Sowter, H.M.1    Corps, A.N.2    Evans, A.L.3
  • 141
    • 34548703367 scopus 로고    scopus 로고
    • Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma
    • Xu L, Jain RK. Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res 2007;5:873-80
    • (2007) Mol Cancer Res , vol.5 , pp. 873-880
    • Xu, L.1    Jain, R.K.2
  • 142
    • 0030091641 scopus 로고    scopus 로고
    • Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas
    • Hatva E, Bohling T, Jaaskelainen J, et al. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 1996;148:763-75
    • (1996) Am J Pathol , vol.148 , pp. 763-775
    • Hatva, E.1    Bohling, T.2    Jaaskelainen, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.